These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy. Karasu B; Akbas YB; Aykut A; Celebi ARC Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031 [TBL] [Abstract][Full Text] [Related]
5. COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY. Cheng CK; Chang CK; Peng CH Retina; 2017 Feb; 37(2):325-333. PubMed ID: 27429374 [TBL] [Abstract][Full Text] [Related]
6. Optical coherent tomographic angiographic pattern of the deep choroidal layer and choriocapillaris after photodynamic therapy for central serous chorioretinopathy. Chan SY; Pan CT; Wang Q; Shi XH; Jonas JB; Wei WB Graefes Arch Clin Exp Ophthalmol; 2019 Jul; 257(7):1365-1372. PubMed ID: 31037490 [TBL] [Abstract][Full Text] [Related]
7. Optical coherence tomography angiography quantification of choriocapillaris blood-flow after half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Le HM; Mrejen S; Sibilia L; Cohen SY Graefes Arch Clin Exp Ophthalmol; 2022 Aug; 260(8):2483-2490. PubMed ID: 35348843 [TBL] [Abstract][Full Text] [Related]
8. Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynamic therapy. Yang HS; Kang TG; Park H; Heo JS; Park J; Lee KS; Choi S PLoS One; 2020; 15(1):e0227718. PubMed ID: 31929582 [TBL] [Abstract][Full Text] [Related]
9. Reduced-fluence photodynamic therapy for subfoveal serous pigment epithelial detachment with choroidal vascular hyperpermeability. Goto S; Gomi F; Ueno C; Nishida K Am J Ophthalmol; 2012 Nov; 154(5):865-871.e1. PubMed ID: 22840480 [TBL] [Abstract][Full Text] [Related]
10. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Maruko I; Iida T; Sugano Y; Ojima A; Ogasawara M; Spaide RF Ophthalmology; 2010 Sep; 117(9):1792-9. PubMed ID: 20472289 [TBL] [Abstract][Full Text] [Related]
11. Multimodal Imaging and Choroidal Volumetric Changes After Half-fluence PDT in Central Serous Chorioretinopathy. Munk MR; Shah R; Pappas F; Baddar D; Wong B; Jampol LM; Fawzi AA Curr Eye Res; 2016; 41(1):97-106. PubMed ID: 25612245 [TBL] [Abstract][Full Text] [Related]
12. Effect of Photodynamic Therapy on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy. Xu Y; Su Y; Li L; Qi H; Zheng H; Chen C Ophthalmologica; 2017; 237(3):167-172. PubMed ID: 28171871 [TBL] [Abstract][Full Text] [Related]
13. Optical coherence tomography angiography to assess vascular remodeling of the choriocapillaris after low-fluence photodynamic therapy for chronic central serous chorioretinopathy. Cennamo G; Cennamo M; Caputo G; Mirra F; Pafundi PC; de Crecchio G; Cennamo G Photodiagnosis Photodyn Ther; 2019 Sep; 27():162-166. PubMed ID: 31163282 [TBL] [Abstract][Full Text] [Related]
14. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes. Matušková V; Vysloužilová D; Uher M Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091 [TBL] [Abstract][Full Text] [Related]
15. Long-Term Outcomes of Full-Fluence and Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy. Son BK; Kim K; Kim ES; Yu SY Ophthalmologica; 2019; 241(2):105-115. PubMed ID: 30110697 [TBL] [Abstract][Full Text] [Related]
17. Comparison between the outcomes of fluorescein angiography-guided and indocyanine green angiography-guided half-time photodynamic therapy for central serous chorioretinopathy. Hayashida M; Miki A; Honda S; Nakamura M Photodiagnosis Photodyn Ther; 2020 Sep; 31():101955. PubMed ID: 32818640 [TBL] [Abstract][Full Text] [Related]
18. Clinical evaluation of neovascular and non-neovascular chronic central serous chorioretinopathy (CSC) diagnosed by swept source optical coherence tomography angiography (SS OCTA). Sulzbacher F; Schütze C; Burgmüller M; Vécsei-Marlovits PV; Weingessel B Graefes Arch Clin Exp Ophthalmol; 2019 Aug; 257(8):1581-1590. PubMed ID: 31037488 [TBL] [Abstract][Full Text] [Related]
19. Early visual and morphologic changes after half-fluence photodynamic therapy in chronic central serous chorioretinopathy. Alkin Z; Ozkaya A; Agca A; Yazici AT; Demirok A J Ocul Pharmacol Ther; 2014 May; 30(4):359-65. PubMed ID: 24456481 [TBL] [Abstract][Full Text] [Related]
20. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial. Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]